159992 创新药
交易中 03-26 10:37:36
资讯
新帖
简况
先声药业(02096)2025年营收达77.31亿元再创新高 创新药收入占比持续提升
智通财经 · 03-25 23:06
先声药业(02096)2025年营收达77.31亿元再创新高 创新药收入占比持续提升
同源康医药-B(02410)将于2026年AACR年会上展示五个创新药项目的研究成果
智通财经 · 03-25 22:42
同源康医药-B(02410)将于2026年AACR年会上展示五个创新药项目的研究成果
远大医药(00512)：中药1类创新药GPN01020在中国获批开展II期临床研究
智通财经 · 03-25 18:04
远大医药(00512)：中药1类创新药GPN01020在中国获批开展II期临床研究
联邦制药附属创新药UBT251 II期临床研究获成功
财中社 · 03-25 12:10
联邦制药附属创新药UBT251 II期临床研究获成功
一图速览 | 当前创新药的预期差在哪里？
华泰睿思 · 03-25 07:12
一图速览 | 当前创新药的预期差在哪里？
【ETF动向】3月24日广发中证创新药产业ETF基金涨2.84%，份额减少1.4亿份
证券之星 · 03-25 06:31
【ETF动向】3月24日广发中证创新药产业ETF基金涨2.84%，份额减少1.4亿份
复星医药(02196)发布2025年报：创新药和全球化双引擎驱动高质量发展
智通财经 · 03-24 19:16
复星医药(02196)发布2025年报：创新药和全球化双引擎驱动高质量发展
信立泰(002294.SZ)：自研创新药物SAL0145注射液获批开展MASH适应症临床试验
智通财经 · 03-24 16:45
信立泰(002294.SZ)：自研创新药物SAL0145注射液获批开展MASH适应症临床试验
跨国药企建言支付体系构建：商保如何扛起创新药发展大旗？
21世纪经济报道 · 03-24 16:34
跨国药企建言支付体系构建：商保如何扛起创新药发展大旗？
创新药盈利拐点确立，富国医药创新股票锚定核心赛道
新浪基金 · 03-24 11:55
创新药盈利拐点确立，富国医药创新股票锚定核心赛道
康哲药业：创新药与独家药增长
证券日报 · 03-23
康哲药业：创新药与独家药增长
四环医药附属创新药III期临床试验完成500名受试者入组
财中社 · 03-22
四环医药附属创新药III期临床试验完成500名受试者入组
百利天恒(688506.SH)创新药BL-ARC002注射液获临床试验批准
智通财经 · 03-22
百利天恒(688506.SH)创新药BL-ARC002注射液获临床试验批准
破解“最后一公里”！商业健康险助力创新药，如何布局？
券商中国 · 03-21
破解“最后一公里”！商业健康险助力创新药，如何布局？
中国首款，驻昌平企业创新药完成首例受试者给药
新京报 · 03-20
中国首款，驻昌平企业创新药完成首例受试者给药
中国银河证券：看好2026年医药行业投资机会 推荐关注创新药、创新器械及医疗AI方向
智通财经 · 03-20
中国银河证券：看好2026年医药行业投资机会 推荐关注创新药、创新器械及医疗AI方向
齐鲁制药创新药QLH2405注射液获批临床，瞄准阿尔茨海默病早期干预
蓝鲸财经 · 03-20
齐鲁制药创新药QLH2405注射液获批临床，瞄准阿尔茨海默病早期干预
“卖水人”迎投资时点！兴业证券孙媛媛：中国创新药一定能产生全球性的跨国企业
券商中国 · 03-19
“卖水人”迎投资时点！兴业证券孙媛媛：中国创新药一定能产生全球性的跨国企业
山西证券：创新药多层次支付体系持续完善 国产全球市场竞争力持续提升
智通财经 · 03-19
山西证券：创新药多层次支付体系持续完善 国产全球市场竞争力持续提升
A股创新药概念震荡走低，科兴制药跌超10%
每日经济新闻 · 03-19
A股创新药概念震荡走低，科兴制药跌超10%
加载更多
公司概况
公司名称：
--
所属市场：
上市日期：
--
主营业务：
发行价格：
--
{"stockData":{"symbol":"159992","market":"SZ","secType":"STK","nameCN":"创新药","latestPrice":0.786,"timestamp":1774492656000,"preClose":0.782,"halted":0,"volume":279117700,"delay":0,"changeRate":0.0051,"floatShares":0,"shares":0,"eps":0,"marketStatus":"交易中","change":0.004,"latestTime":"03-26 10:37:36","open":0.781,"high":0.794,"low":0.78,"amount":220000000,"amplitude":0.0179,"askPrice":0.787,"askSize":143337,"bidPrice":0.786,"bidSize":2726,"shortable":0,"etf":1,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1774495800000},"marketStatusCode":2,"adr":0,"adjPreClose":0.782,"symbolType":"fund","openAndCloseTimeList":[[1774488600000,1774495800000],[1774501200000,1774508400000]],"highLimit":0.86,"lowLimit":0.704,"ibTradeSell":false,"ibTradeBuySell":true,"isCdr":false,"pbRate":0,"committee":0.058433,"marketValue":0,"turnoverRate":0,"status":0,"floatMarketCap":0},"requestUrl":"/m/hq/s/159992","defaultTab":"news","newsList":[{"id":"2622077226","title":"先声药业(02096)2025年营收达77.31亿元再创新高 创新药收入占比持续提升","url":"https://stock-news.laohu8.com/highlight/detail?id=2622077226","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622077226?lang=zh_cn&edition=full","pubTime":"2026-03-25 23:06","pubTimestamp":1774451165,"startTime":"0","endTime":"0","summary":"智通财经APP讯，先声药业 公布2025年业绩，收入人民币77.31亿元，同比增长16.5%;创新药业务收入人民币63.04亿元，占总收入比率81.5%，较2024年增长27.9%。归属于公司权益股东的利润人民币13.44亿元，同比增长86.2%;经调整归属于公司权益股东的利润人民币12.80亿元，同比增长27.1%。公告称，收入增长主要归因于创新药收入及授权许可收入的增加。创新药业务加速增长，商业化创新药已拓展至十款，营收再创新高，创新药收入占比持续提升。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419114.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159992","06978","02096"],"gpt_icon":0},{"id":"2622072086","title":"同源康医药-B(02410)将于2026年AACR年会上展示五个创新药项目的研究成果","url":"https://stock-news.laohu8.com/highlight/detail?id=2622072086","media":"智通财经","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622072086?lang=zh_cn&edition=full","pubTime":"2026-03-25 22:42","pubTimestamp":1774449755,"startTime":"0","endTime":"0","summary":"智通财经APP讯，同源康医药-B(02410)发布公告，本公司将于2026年美国癌症研究协会(AACR)年会壁报环节展示TY-0609(CDK4抑制剂)、TY-2699a(CDK7抑制剂 )、 TY-2719(EGFR/FAK(PROTAC)抑制剂)、PI3Kα(PI3Kα抑制剂)、TY-1054 (YAP-TEAD抑制剂)五个在研创新药项目的研究进展和成果，此次展示的五个项目均为本公司自主研发的抗肿瘤小分子创新候选药物。本届AACR年会将于2026 年4月17日至22日在美国圣地亚哥举行，本公司参会壁报将分别于4月19日至4月 21日展示。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419089.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","09939","BK1574","159992","06978","02410","BK1161","159938"],"gpt_icon":0},{"id":"2622024791","title":"远大医药(00512)：中药1类创新药GPN01020在中国获批开展II期临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2622024791","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622024791?lang=zh_cn&edition=full","pubTime":"2026-03-25 18:04","pubTimestamp":1774433064,"startTime":"0","endTime":"0","summary":"智通财经APP讯，远大医药 发布公告，近日，集团用于预防性治疗偏头痛的中药创新药GPN01020正式获得中华人民共和国国家药品监督管理局(药监局)批准开展II期临床研究。前期数百人的研究者发起的临床研究结果显示，GPN01020在减少偏头痛发作天数与发作频次、改善偏头痛相关症状等方面表现出良好疗效与安全性。集团的GPN01020有望为临床提供一种新的治疗选择。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418815.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1142","06978","BK1574","BK1094","BK1191","00512","159992","BK1161","01020"],"gpt_icon":0},{"id":"2622104945","title":"联邦制药附属创新药UBT251 II期临床研究获成功","url":"https://stock-news.laohu8.com/highlight/detail?id=2622104945","media":"财中社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622104945?lang=zh_cn&edition=full","pubTime":"2026-03-25 12:10","pubTimestamp":1774411800,"startTime":"0","endTime":"0","summary":"3月25日，联邦制药（03933）发布公告，宣布其全资附属公司联邦生物科技（珠海横琴）有限公司自主研发的1类创新药UBT251注射液已完成在中国2型糖尿病患者中的II期临床研究。此次研究共纳入211名患者，基线平均糖化血红蛋白（HbA1c）为8.12%，基线体重为80.1kg，基线BMI为29.1kg/m2。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603253683821422.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["03933","BK1191","BK1574","159992","06978","BK1161"],"gpt_icon":0},{"id":"2622049074","title":"一图速览 | 当前创新药的预期差在哪里？","url":"https://stock-news.laohu8.com/highlight/detail?id=2622049074","media":"华泰睿思","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622049074?lang=zh_cn&edition=full","pubTime":"2026-03-25 07:12","pubTimestamp":1774393920,"startTime":"0","endTime":"0","summary":"相关研报：华泰 | 医药：BD中国模式 - 可持续现金流有望重塑估值","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzA5NDI5MDQwMg==&mid=2649846967&idx=4&sn=4406a78aac8028b89cf20d75fd45a634&chksm=89674059f78aeefef08e23d3c130dae7eecb81b079e60543c71f17815e3dcf920e53e3e4b9e3&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["BK1161","06978","BK1574","159992"],"gpt_icon":0},{"id":"2622191880","title":"【ETF动向】3月24日广发中证创新药产业ETF基金涨2.84%，份额减少1.4亿份","url":"https://stock-news.laohu8.com/highlight/detail?id=2622191880","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622191880?lang=zh_cn&edition=full","pubTime":"2026-03-25 06:31","pubTimestamp":1774391485,"startTime":"0","endTime":"0","summary":"证券之星消息，3月24日，广发中证创新药产业ETF基金（515120）涨2.84%，成交额2.52亿元。当日份额减少了1.4亿份，最新份额为144.99亿份，近20个交易日份额增加2.75亿份。当日资金净流入1.69亿元（资金流向是当日计算的资产净值和上一交易日计算的资产净值相减得出的），最新资产净值计算值为84.25亿元。广发中证创新药产业ETF基金跟踪标的为中证创新药产业指数，成立（2020-12-03）以来超额回报为-1.7%，近一个月超额回报为-0.02%，管理人为广发基金公司，基金经理为罗国庆。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032500008177.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK1574","159992","06978"],"gpt_icon":0},{"id":"2621069488","title":"复星医药(02196)发布2025年报：创新药和全球化双引擎驱动高质量发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2621069488","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621069488?lang=zh_cn&edition=full","pubTime":"2026-03-24 19:16","pubTimestamp":1774350963,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，复星医药(600196.SH，02196)公布2025年度经营业绩。复星医药以创新研发突破与全球化体系升级为双引擎，实现营业收入人民币416.62亿元，同比增长1.45%，其中，创新药品收入98.93亿元，同比增长29.59%;境外收入129.77亿元，同比增长14.87%，两大核心指标实现双增长，深化复星医药高质量发展的底层逻辑。归母净利润33.71亿元，同比增长21.69%;归母扣非净利润23.40亿元，同比增长1.12%;经营活动产生的现金流量净额为52.13亿元，同比增长16.45%，高质量发展底座进一步夯实。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418167.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK0060","BK1191","159992","BK1515","BK1593","BK0188","BK1574","BK0096","06978","BK0187","BK0028","02196","BK0196","BK0012","BK0239","BK0183","BK0175","600196"],"gpt_icon":0},{"id":"2621057186","title":"信立泰(002294.SZ)：自研创新药物SAL0145注射液获批开展MASH适应症临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2621057186","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621057186?lang=zh_cn&edition=full","pubTime":"2026-03-24 16:45","pubTimestamp":1774341908,"startTime":"0","endTime":"0","summary":"智通财经APP讯，信立泰(002294.SZ)发布公告，近日，公司收到国家药品监督管理局核准签发的《临床试验批准通知书》，同意公司自主研发的创新药物SAL0145注射液(项目代码：SAL0145)开展MASH适应症的临床试验。SAL0145是公司研发的具有自主知识产权的siRNA药物。临床前研究显示，其具有治疗MASH的潜力。若能研发成功并获批上市，将有望为更多患者提供新的用药选择，满足未被满足的临床需求，并进一步丰富公司慢病领域的创新产品管线。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418019.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0183","159992","06978","BK0196","002294","BK0187","BK1161","BK0028","BK0239","BK0188","BK1574"],"gpt_icon":0},{"id":"2621072057","title":"跨国药企建言支付体系构建：商保如何扛起创新药发展大旗？","url":"https://stock-news.laohu8.com/highlight/detail?id=2621072057","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621072057?lang=zh_cn&edition=full","pubTime":"2026-03-24 16:34","pubTimestamp":1774341240,"startTime":"0","endTime":"0","summary":"“十五五”开局之年，生物医药产业迎来了前所未有的战略定位。今年两会政府工作报告首次将生物医药与人工智能、新能源等并列，上升为国家六大新兴支柱产业。这一顶层设计的跃迁，标志着生物医药不再仅仅是关系国计民生的战略性产业，更被寄予了驱动经济高质量发展的厚望。然而，从“战略性产业”到“支柱产业”，并非简单的政策升格，而是对产业生态系统的全方位考验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://biz.eastmoney.com/a/202603243682596370.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://biz.eastmoney.com/a/202603243682596370.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159992","BK1574","06978","BK1161"],"gpt_icon":0},{"id":"2621741037","title":"创新药盈利拐点确立，富国医药创新股票锚定核心赛道","url":"https://stock-news.laohu8.com/highlight/detail?id=2621741037","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621741037?lang=zh_cn&edition=full","pubTime":"2026-03-24 11:55","pubTimestamp":1774324500,"startTime":"0","endTime":"0","summary":"近日，国产创新药BD出海交易金额的爆发式增长，引发了市场广泛关注。一个明显的行业趋势是，国内创新药行业正通过 BD 业务的稳步发展实现质变，License-out的、不仅让国产创新药站上全球舞台，更推动行业迎来盈利拐点，成为医药领域的核心投资主线。 而精准布局创新药及其产业链的富国医药创新股票，踩中License-out爆发和盈利拐点的风口，迎来配置良机。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/jjh/2026-03-24/doc-inhsaeyu0524172.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1515","159938","159992","09939","BK1161","06978","BK1574"],"gpt_icon":0},{"id":"2621743834","title":"康哲药业：创新药与独家药增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2621743834","media":"证券日报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621743834?lang=zh_cn&edition=full","pubTime":"2026-03-23 00:16","pubTimestamp":1774196160,"startTime":"0","endTime":"0","summary":"近日，康哲药业控股有限公司（以下简称“康哲药业”）发布2025年度业绩公告，全面展现战略转型成效。财报显示，公司业绩已重回长周期增长轨道，创新药与独家药成为核心增长引擎，集采影响基本出清，叠加多款重磅新药密集获批与管线稳步推进，长期发展动能全面焕新。2025年是康哲药业战略转型的关键收获年。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603233679834735.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IE00BVYPNQ40.USD","IE00BVYPNP33.GBP","SG9999015986.USD","SG9999004220.SGD","159992","SG9999015952.SGD","IE00BGHQDM52.EUR","BK1161","06978","BK1191","BK1574","00867","BK1593","IE00BMCWC346.EUR","SG9999015945.SGD","SG9999015978.USD","LU2488822045.USD","IE00BYV24P56.USD"],"gpt_icon":1},{"id":"2621124714","title":"四环医药附属创新药III期临床试验完成500名受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2621124714","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621124714?lang=zh_cn&edition=full","pubTime":"2026-03-22 18:34","pubTimestamp":1774175640,"startTime":"0","endTime":"0","summary":"3月22日，四环医药（00460）发布公告，本公司旗下非全资附属公司轩竹生物科技股份有限公司的创新药安奈拉唑钠肠溶片（商品名：安久卫?）用于治疗成人反流性食管炎的中国III期临床试验已顺利完成全部500名受试者入组。该试验是一项多中心、随机、双盲双模拟、阳性药物平行对照的关键性研究，旨在评估安奈拉唑钠肠溶片治疗中国成年反流性食管炎受试者的有效性和安全性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603223679754978.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1593","BK1600","00460","06978","159992","BK1515","BK1161","III","BK1574","BK1191","BK4134"],"gpt_icon":0},{"id":"2621371933","title":"百利天恒(688506.SH)创新药BL-ARC002注射液获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2621371933","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621371933?lang=zh_cn&edition=full","pubTime":"2026-03-22 15:41","pubTimestamp":1774165288,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百利天恒(688506.SH)公告，公司近日收到国家药品监督管理局(NMPA)正式批准签发的《药物临床试验批准通知书》，公司自主研发的创新药BL-ARC002注射液的药物临床试验获得批准。公告称，BL-ARC002通过抗体介导的精准靶向递送技术及放射性核素强大的肿瘤杀伤能力，与传统放射性核素偶联药物相比，具有更强的靶点特异性、更高的肿瘤富集性，并有望展现出更好的抗耐药性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417046.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159992","BL","91194","02615","BK1161","LU1815336091.USD","BK4023","BK1574","06978","LU0757428866.USD","688506","BK0239"],"gpt_icon":0},{"id":"2621769781","title":"破解“最后一公里”！商业健康险助力创新药，如何布局？","url":"https://stock-news.laohu8.com/highlight/detail?id=2621769781","media":"券商中国","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621769781?lang=zh_cn&edition=full","pubTime":"2026-03-21 09:35","pubTimestamp":1774056900,"startTime":"0","endTime":"0","summary":"不过，创新药械目前尚存在落地“最后一公里”难题，尤其是高值创新药仍面临“进院难、支付难”问题，可及性不足。从“单一主体”到“双轨支付”保险业对于商业健康保险协同促进创新药械发展充满期待。商保目录的推出意味着，基本医保报销不了的创新药，进入商保目录后，将有望由商业健康保险来报销，从而提高患者对创新药用药的可及性。另一方面，孙洁建议赋予商业健康保险公司高值创新药用药指南和临床路径编制权，","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzA3NjM5MjIwOQ==&mid=2652259179&idx=3&sn=720c605e9b1f9048995e83e93e9f51b6&chksm=8512a615e67cf164a38dda77aaf35ea62861109c1b23c72b14ea4548758a65f25eaaa85d77cc&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["BK1161","BK1574","06978","159992"],"gpt_icon":0},{"id":"2620202294","title":"中国首款，驻昌平企业创新药完成首例受试者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2620202294","media":"新京报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620202294?lang=zh_cn&edition=full","pubTime":"2026-03-20 13:29","pubTimestamp":1773984540,"startTime":"0","endTime":"0","summary":"新京报讯 据“北京昌平”微信公众号消息，未来科学城生命谷企业诺诚健华近日宣布，中国首款、全球第二款进入临床的VAV1分子胶降解剂ICP-538完成首例受试者给药。目前，全球尚无获批上市的VAV1靶向药物。诺诚健华联合创始人董事长兼CEO崔霁松表示，VAV1分子胶作为一种新型的靶向治疗药物，具有靶向性强、多重作用机制和有效性高三大优势，希望ICP-538成为治疗自身免疫性疾病的新希望。","market":"sh","thumbnail":"https://media.bjnews.com.cn/cover/2026/03/20/5699047677929529541.png?x-oss-process=image/resize,m_lfit,w_365","type":0,"news_type":0,"thumbnails":["https://media.bjnews.com.cn/cover/2026/03/20/5699047677929529541.png?x-oss-process=image/resize,m_lfit,w_365"],"rights":{"source":"highlight_bjnews","url":"https://www.bjnews.com.cn/detail/1773983156129729.html","rn_cache_url":null,"customStyle":"handleCustomStyle(customStyle, ThemeStyle, getFont(fontSize))","selectors":"#main .nleft","filters":".ntit, .attitude","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.bjnews.com.cn/detail/1773983156129729.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_bjnews","symbols":["06978","159992","BK1574","BK1161"],"gpt_icon":0},{"id":"2620209049","title":"中国银河证券：看好2026年医药行业投资机会 推荐关注创新药、创新器械及医疗AI方向","url":"https://stock-news.laohu8.com/highlight/detail?id=2620209049","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620209049?lang=zh_cn&edition=full","pubTime":"2026-03-20 10:58","pubTimestamp":1773975498,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中国银河证券发布研报称，十五五规划预计将持续推动生物医药行业发展，看好2026年医药行业投资机会，近期震荡调整后估值已回落至相对低位，有望重启升势，投资思路上寻找医药硬科技和细分赛道α，推荐关注创新药、创新器械、医疗AI方向，关注医药消费复苏及独立第三方ICL。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1416382.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","150261","06978","161027","159992","BK1564","BK1147","06881","BK0188","601881","BK1161","BK0276"],"gpt_icon":0},{"id":"2620066342","title":"齐鲁制药创新药QLH2405注射液获批临床，瞄准阿尔茨海默病早期干预","url":"https://stock-news.laohu8.com/highlight/detail?id=2620066342","media":"蓝鲸财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620066342?lang=zh_cn&edition=full","pubTime":"2026-03-20 10:24","pubTimestamp":1773973496,"startTime":"0","endTime":"0","summary":"3月13日，据国家药品监督管理局药品审评中心官网显示，齐鲁制药自主研发的1类新药QLH2405注射液获得临床试验默示许可，拟定适应症为阿尔茨海默病源性轻度认知障碍和轻度阿尔茨海默病。作为一种慢性、进行性神经退行性疾病，阿尔茨海默病起病隐匿且早期干预窗口极为关键。获批临床后，齐鲁制药将继续秉持科学、严谨、规范的原则，加快推进临床试验，力争全面评估QLH2405注射液在目标人群中的安全性及有效性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1773973135107607202","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["159992","BK1161","06978","BK1191","BK1574","01477"],"gpt_icon":0},{"id":"2620935276","title":"“卖水人”迎投资时点！兴业证券孙媛媛：中国创新药一定能产生全球性的跨国企业","url":"https://stock-news.laohu8.com/highlight/detail?id=2620935276","media":"券商中国","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620935276?lang=zh_cn&edition=full","pubTime":"2026-03-19 23:03","pubTimestamp":1773932580,"startTime":"0","endTime":"0","summary":"中国一定能产生全球性的MNC券商中国记者：从您的角度来看，现在中国创新药在世界上处于什么样的水平？后续，中国一定能产生全球性的MNC。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzA3NjM5MjIwOQ==&mid=2652259019&idx=3&sn=2c859608e1e83d85c4d3fdb584034f4f&chksm=85db8db51946a0cdf8a6475aa3e133f4cef46ec3e1d878aef2c0e136772181e268ff30d795b3&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["BK1574","BK0276","BK0012","06978","601377","159992","BK1161","BK0188","BK0183","BK0028"],"gpt_icon":0},{"id":"2620212622","title":"山西证券：创新药多层次支付体系持续完善 国产全球市场竞争力持续提升","url":"https://stock-news.laohu8.com/highlight/detail?id=2620212622","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620212622?lang=zh_cn&edition=full","pubTime":"2026-03-19 15:21","pubTimestamp":1773904871,"startTime":"0","endTime":"0","summary":"中国创新药BD授权金额快速增长体现出中国创新药产业的快速发展和国际竞争力的提升。商业健康险迎来大发展，多层次支付体系支持创新药&器械发展2024年7月国常会审议通过《全链条支持创新药发展实施方案》，提出发展商业保险，合力助推创新药发展。国家医保局也多次表态探索创新药的多元支付机制，支持引导普惠型商业健康保险及时将创新药品纳入报销范围。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1415872.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK0276","159992","BK0183","BK1161","06978","BK1574","BK0188","002500"],"gpt_icon":0},{"id":"2620211360","title":"A股创新药概念震荡走低，科兴制药跌超10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620211360","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620211360?lang=zh_cn&edition=full","pubTime":"2026-03-19 14:30","pubTimestamp":1773901800,"startTime":"0","endTime":"0","summary":"每经AI快讯，3月19日，A股创新药概念震荡走低，科兴制药跌超10%，益诺思、海特生物、艾迪药业、皓元医药、北陆药业跌幅居前。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2026-03-19/doc-inhrnzrv8758486.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-03-19/doc-inhrnzrv8758486.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","399300","159992","06978","BK1574","688136","BK0239","159982"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1774492659408,"stockEarnings":[{"period":"1week","weight":-0.0369},{"period":"1month","weight":-0.0601},{"period":"3month","weight":-0.0864},{"period":"6month","weight":-0.1734},{"period":"1year","weight":0.0846},{"period":"ytd","weight":-0.059}],"compareEarnings":[{"period":"1week","weight":-0.0323},{"period":"1month","weight":-0.0368},{"period":"3month","weight":-0.007},{"period":"6month","weight":0.0271},{"period":"1year","weight":0.1667},{"period":"ytd","weight":-0.0093}],"compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"创新药(159992)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供创新药(159992)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"创新药,159992,创新药股票,创新药股票老虎,创新药股票老虎国际,创新药行情,创新药股票行情,创新药股价,创新药股市,创新药股票价格,创新药股票交易,创新药股票购买,创新药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"创新药(159992)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供创新药(159992)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}